Phenotypes for Avpr2 Tg(CAG-cre/Esr1*)5Amc MGI:7282305 MGI Mouse

behavior/neurological

polydipsia ( J:324922 )

• 7- to 8-week-old males treated with tamoxifen for 6 days show an increase in water intake

• treatment with the selective EP4 receptor agonist ONO results in a 50% decrease in cumulative water consumption

renal/urinary system

decreased urine creatinine level ( J:324922 )

• tamoxifen-treated males show a reduction in urine creatinine concentration

decreased urine potassium level ( J:324922 )

• tamoxifen-treated males show a reduction in urine potassium concentration

decreased urine sodium level ( J:324922 )

• tamoxifen-treated males show a reduction in urine sodium concentration

• however, serum sodium levels are normal

decreased urine osmolality ( J:324922 )

• urine produced by tamoxifen-treated males has very low osmolality

• urine osmolality is lower by about 25% even prior to tamoxifen treatment

• treatment with 1-desamino-8-D-AVP, a selective AVPR2 agonist, is unable to increase urine osmolality in tamoxifen-treated mice

• treatment with the selective EP4 receptor agonist ONO leads to dose-dependent increases in urine osmolality in tamoxifen-administered mice

decreased urine urea nitrogen level ( J:324922 )

• tamoxifen-treated males show a reduction in urine urea

hydronephrosis ( J:324922 )

• kidneys show distention of the renal pelvis after tamoxifen treatment

• ONO treatment completely prevents further expansion of renal pelvic space in tamoxifen-administered mice

decreased renal glomerular filtration rate ( J:324922 )

• tamoxifen-treated males show an approximate 40% reduction of glomerular filtration rate

• ONO treatment restores normal glomerular filtration rate in tamoxifen-administered mice

polyuria ( J:324922 )

• 7- to 8-week-old males treated with tamoxifen for 6 days show an increase in urine production

• treatment with the selective EP4 receptor agonist ONO leads to a reduction in urine output in tamoxifen-administered mice

homeostasis/metabolism